Bruker Co.

Bruker reported Q3 revenue of $874 million and adjusted earnings of $0.56 per share, both above analysts’ estimates. The company reaffirmed its full-year guidance of $3.52–3.56 billion in revenue and adjusted earnings of $2.10–2.15 per share. Bruker said it saw strong AI-driven demand for metrology tools for memory chips and high order intake from areas such as superconducting wire, fusion energy and high-energy physics, prompting a sharp rise in its stock. » Mere på deraktionaer.de

Bruker reported at the Wells Fargo Healthcare Conference strong order intake driven by semiconductor metrology, defense/air‑security systems and fusion research, with a book‑to‑bill ratio above 1.0 and organic order growth of more than 10% year‑on‑year. Earnings per share for Q2 2024 were well above consensus and the company’s guidance, supported by cost cuts and tariff/duty differentials. Management warned of longer delivery cycles, so revenues are lagging orders, but expects roughly 5% organic revenue growth for Q4 2024 and sees longer‑term growth potential especially in China, proteomics and AI‑enabled life‑science applications from 2025. Bruker emphasizes the strategic prioritization of margin‑rich deep‑tech areas despite timing delays in revenue realization. » Mere på de.investing.com

Bruker’s board declared a quarterly cash dividend of $0.05 per common share, payable October 7, 2026, to shareholders of record at the close of business on September 21, 2026. At a share price of $57.70, the dividend equates to a yield of about 0.35%. Bruker beat adjusted earnings expectations in the second quarter, but missed revenue and issued a cautious outlook; Stifel raised its price target to $50 while keeping its rating at "Hold." » Mere på de.investing.com

Bruker reported adjusted earnings of $0.49 per share for Q2, well above the consensus estimate of $0.3832, while revenue of $838.5 million missed the estimate of $853.39 million. Improved margins (Non-GAAP gross margin 52.1%, operating margin 14.1%) and cost reductions boosted profitability, but organic revenue growth remained subdued at 2.8%. The stock fell about 16.8% to $53.50 after the announcement as investors weighed the weaker revenue and a cautious near-term outlook. Bruker reiterated full-year EPS guidance of $2.10–$2.15 and expects flat to slightly higher organic revenue growth in Q3 with modest margin pressure, with a more pronounced recovery anticipated in Q4. » Mere på de.investing.com

JPMorgan raised its price target on Bruker to $65 from $45 and maintained an Overweight rating. Bruker showcased advances at ASM Microbe 2026 across microbiology and infection diagnostics, including FDA‑approved updates to its MALDI Biotyper CA system that now spots 549 clinically validated species and workflow/software upgrades. The company also introduced expanded research-use libraries covering 5,325 species and is developing a rapid antimicrobial susceptibility testing workflow to speed clinical decision‑making. » Mere på finance.yahoo.com